二甲双胍直接触发人肠道黏膜分泌PYY
该研究用46例结肠和9例回肠手术切除黏膜组织行体外分泌实验,发现二甲双胍暴露15分钟即可增加回肠(P<0.05)和结肠(P<0.001)上皮的PYY分泌,且该效应不随BMI或2型糖尿病状态改变;机制涉及PMAT和SERT介导的细胞内化及AMPK激活。
要点
- 二甲双胍直接作用于人肠道上皮,急性触发PYY分泌。
- 该效应在回肠和结肠均存在,且不受BMI或2型糖尿病影响。
- PMAT、SERT抑制剂及AMPK抑制剂可阻断二甲双胍诱导的PYY分泌。
核心结论
- 二甲双胍通过PMAT和SERT内化入细胞并激活AMPK,直接触发人肠道上皮分泌PYY。
- 结果支持二甲双胍治疗代谢综合征具有肠道作用成分。
研究设计与样本
- 体外实验:取46例人结肠和9例回肠手术切除黏膜组织,行静态孵育分泌实验。
- 组织暴露于二甲双胍及其他化合物,15分钟后取上清,ELISA测PYY。
主要发现
- 二甲双胍增加回肠上皮PYY分泌(P<0.05)。
- 二甲双胍增加结肠上皮PYY分泌(P<0.001)。
- 基础和二甲双胍诱导的PYY分泌在不同BMI或2型糖尿病个体组织中无变化。
- PMAT抑制剂、SERT抑制剂及AMPK抑制剂均阻断二甲双胍依赖的PYY分泌。
临床怎么用
- 二甲双胍的减重和代谢改善作用可能部分由肠道PYY分泌介导。
- PMAT/SERT/AMPK通路或为增强二甲双胍肠道效应的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The antidiabetic drug metformin causes weight loss, but the underlying mechanisms are unclear. Recent clinical studies show that metformin increases plasma levels of the anorectic gut hormone, peptide YY (PYY), but whether this is through a direct effect on the gut is unknown. OBJECTIVE: We hypothesized that exposure of human gut mucosal tissue to metformin would acutely trigger PYY secretion. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS: Mucosal tissue was prepared from 46 human colonic and 9 ileal samples obtained after surgical resection and ex vivo secretion assays were performed. Tissue was exposed to metformin, as well as a series of other compounds as part of our mechanistic studies, in static incubations. Supernatant was sampled after 15 minutes. MAIN OUTCOME MEASURES: PYY levels in supernatant, measured using ELISA. RESULTS: Metformin increased PYY secretion from both ileal (P < 0.05) and colonic (P < 0.001) epithelia. Both basal and metformin-induced PYY secretion were unchanged across body mass index or in tissues obtained from individuals with type 2 diabetes. Metformin-dependent PYY secretion was blocked by inhibitors of the plasma membrane monoamine transporter (PMAT) and the serotonin reuptake transporter (SERT), as well as by an inhibitor of AMP kinase (AMPK). CONCLUSIONS: This is a report of a direct action of metformin on the gut epithelium to trigger PYY secretion in humans, occurring via cell internalization through PMAT and SERT and intracellular activation of AMPK. Our results provide further support that the role of metformin in the treatment of metabolic syndrome has a gut-based component.
引用
- Sun EW, Martin AM, Wattchow DA, et al. Metformin Triggers PYY Secretion in Human Gut Mucosa. J Clin Endocrinol Metab. 2019. PMID: 30759215. doi:10.1210/jc.2018-02460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。